I've had a heart attack. Is semaglutide safe for me?

In men with prior myocardial infarction who are overweight or obese and non-diabetic, semaglutide is not merely safe, it is specifically indicated as a cardiovascular risk reduction agent by the SELECT trial evidence. The trial enrolled men who had established CVD (which includes prior MI) and found a 20% reduction in subsequent MACE. The man who had a heart attack 18 months ago, has gained weight since then, and is being considered for semaglutide by his internist is exactly the population that SELECT enrolled.

That said, individualization matters. Contraindications exist: personal or family history of medullary thyroid carcinoma (MEN2 syndrome), prior pancreatitis, severe gastroparesis, and severe renal impairment require careful physician evaluation before initiating GLP-1 therapy. These are not common in most men with prior MI, but the screening matters. GLP-1 agonists also increase resting heart rate by approximately 2–4 beats per minute, a clinically expected and benign effect in most patients, but one worth monitoring in men with prior arrhythmia or autonomic dysfunction. (Lincoff et al., NEJM, 2023)

Cardiologist's calibrated position, Solid (1) for the benefit-risk profile in post-MI patients with elevated BMI and no specific contraindications.

What to do: The conversation is straightforward: bring the SELECT trial reference to your cardiologist and ask whether you fit the enrollment profile. If you have any of the contraindications listed above, clarify those specifically.

For the full picture, read The Drug That Surprised Cardiologists.